Non-invasive Breath Analysis of Pulmonary Nodules

Slides:

Advertisements

Similar presentations

Breath Analysis For Lung Cancer Early Detection Ori Liran a, Manal Abud-Hawa b, Maya Ilouze a,c, Naomi Gai-Mor a, Shlomi Dekel a, Alon Ben-Nun d, Amir.

Advertisements

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Erratum Journal of Thoracic Oncology

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer Inbar Nardi-Agmon, MD, Manal Abud-Hawa, MSc, Ori Liran, MSc, Naomi.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Results of Surgical Treatment for Patients with Small Cell Lung Cancer

Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer Inbar Nardi-Agmon, MD, Manal Abud-Hawa, MSc, Ori Liran, MSc, Naomi.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Detection of Lung Cancer and EGFR Mutation by Electronic Nose System

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer Xiaoxia Chen,

Stephen A. Deppen, PhD, Jeffrey D. Blume, PhD, Melinda C

Electronic Updates for JTO Readers

Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer

A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis María Uribarri, PhD, Itsaso Hormaeche, PhD, Rafael Zalacain, MD,

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer David J. Stewart, MD, Maria I. Nunez, MD,

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Value of circulating insulin-like growth factor–associated proteins for the detection of stage I non–small cell lung cancer John C. Kubasiak, MD, Christopher.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Detection of Lung Cancer by Automated Sputum Cytometry

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer Peter J. Mazzone, MD, MPH, Xiao-Feng.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

A Prognostic Model to Predict Mortality among Non–Small-Cell Lung Cancer Patients in the U.S. Military Health System Jie Lin, PhD, MPH, Corey A. Carter,

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Laurie A. Hohberger, MD, Darrell R. Schroeder, MS, Brian J

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer Mohammad Chakra, MD, Jean Louis Pujol,

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD, Yasunori Sohara, MD, Ryosuke Tsuchiya, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Genetic Changes in Squamous Cell Lung Cancer: A Review

Ethnic Differences in the Management of Lung Cancer in New Zealand

BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced,

Transcutaneous Computed Bioconductance Measurement in Lung Cancer: A Treatment Enabling Technology Useful for Adjunctive Risk Stratification in the Evaluation.

International Thymic Malignancies Interest Group: A Way Forward

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Who should decide margin length in pulmonary excision of lung cancer?

Mark I. Block, MD The Annals of Thoracic Surgery

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Outcome after Pulmonary Metastasectomy: Analysis of 5 Years Consecutive Surgical Resections 2002–2006 Kåre Hornbech, MD, Jesper Ravn, MD, Daniel Andreas.

Mark A. Socinski, MD Journal of Thoracic Oncology

MiR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non- small Cell Lung Cancer Kristen M. Foss, BS, Chao Sima, PhD, Donatella Ugolini,

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Non-invasive Breath Analysis of Pulmonary Nodules Nir Peled, MD, PhD, Meggie Hakim, MSc, Paul A. Bunn, MD, York E. Miller, MD, Timothy C. Kennedy, MD, Jane Mattei, MD, PhD, John D. Mitchell, MD, Fred R. Hirsch, MD, PhD, Hossam Haick, PhD Journal of Thoracic Oncology Volume 7, Issue 10, Pages 1528-1533 (October 2012) DOI: 10.1097/JTO.0b013e3182637d5f Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 One potential biomarker for differentiating malignant lung nodules from benign ones found by means of gas chromatography with mass spectrometry. 1-octene shows a statistically significant difference in the peak area of the benign and malignant samples (p = 0.0486). The positions of the mean values for benign and malignant states are marked with □, the boxes correspond to their 95% confidence limits, and the error bars correspond to the SD. Journal of Thoracic Oncology 2012 7, 1528-1533DOI: (10.1097/JTO.0b013e3182637d5f) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Graphical representation of the first canonical score values for patients with benign nodules and malignant nodules that were obtained from a chemical nanoarray containing 5-nm gold nanoparticle sensors and an organically functionalized carbon nanotube sensor. A, Each point represents one patient. The positions of the mean values are marked with □, the boxes correspond to the 95% confidence limits, and the error bars correspond to the SDs. The confidence intervals are significantly separated (p < 0.0001). B, Receiver operating characteristic curve for the discrimination between malignant and benign pulmonary nodules (PNs), AUC 0.986. AUC, area under the curve. Journal of Thoracic Oncology 2012 7, 1528-1533DOI: (10.1097/JTO.0b013e3182637d5f) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Graphical representation of the first canonical score values for patients with malignant nodules, which differentiate between adenocarcinoma and squamous cell lung cancer, obtained from a chemical nanoarray containing gold nanoparticle sensors. Each point represents one patient. The positions of the mean values are marked with □, the boxes correspond to their 95% confidence limits, and the error bars correspond to the SDs. The confidence intervals are significantly separated (p < 0.0001). Journal of Thoracic Oncology 2012 7, 1528-1533DOI: (10.1097/JTO.0b013e3182637d5f) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Graphical representation of the first canonical score values for patients with early-stage or advanced non–small-cell lung cancer nodules that were obtained from a chemical nanoarray containing seven gold nanoparticle sensors and an organically functionalized carbon nanotube sensor. Each point represents one patient. The positions of the mean values are marked with □, the boxes correspond to their 95% confidence limits, and the error bars correspond to the SDs. The confidence intervals are significantly separated (p < 0.0001). Journal of Thoracic Oncology 2012 7, 1528-1533DOI: (10.1097/JTO.0b013e3182637d5f) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions